Currently, there are 2.03B common shares owned by the public and among those 2.03B shares have been available to trade.
The company’s stock has a 5-day price change of -4.84% and 12.89% over the past three months. BMY shares are trading 8.89% year to date (YTD), with the 12-month market performance up to 8.55% higher. It has a 12-month low price of $39.35 and touched a high of $61.08 over the same period. BMY has an average intraday trading volume of 11.09 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -3.89%, 0.15%, and 13.72% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Bristol-Myers Squibb Co (NYSE: BMY) shares accounts for 77.73% of the company’s 2.03B shares outstanding.
It has a market capitalization of $112.31B and a beta (3y monthly) value of 0.45. The earnings-per-share (ttm) stands at -$3.60. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.31% over the week and 2.26% over the month.
Earnings per share for the fiscal year are expected to decrease by -87.94%, and 680.97% over the next financial year. EPS should shrink at an annualized rate of -5.00% over the next five years, compared to 5.14% over the past 5-year period.
Looking at the support for the BMY, a number of firms have released research notes about the stock. Jefferies stated their Buy rating for the stock in a research note on December 16, 2024, with the firm’s price target at $70. BofA Securities coverage for the Bristol-Myers Squibb Co (BMY) stock in a research note released on December 10, 2024 offered a Neutral rating with a price target of $63. Leerink Partners on their part issued Outperform rating on November 12, 2024.
